Clinical Edge Journal Scan

Prior proton-pump inhibitor use ups migraine risk


Key clinical point: Prior use of proton pump inhibitors (PPI) increased the risk for incident migraine with or without aura irrespective of the history and duration of use.

Major finding: Compared with non-use, past and current use of PPI increased the odds of migraine by 2.56-fold (P < .001) and 4.66-fold (P < .001), respectively, with the risk being persistent for migraine with or without aura (P < .001) and higher with PPI use for ≥30 (adjusted odds ratio [aOR] 4.41; P < .001) vs <30 (aOR 2.49; P < .001) days.

Study details: This retrospective, nested case-control study included 28,159 patients with incident migraine with or without aura and 112,636 propensity score-matched control participants.

Disclosures: This study was funded by the National Research Foundation of Korea from the Korean Ministry of Science and ICT. The authors declared no conflicts of interest.

Source: Kang HS et al. Association between migraines and prior proton pump inhibitor use: A nested case-control study using a national health screening cohort. Pharmaceuticals (Basel). 2022;15(11):1385 (Nov 10). Doi: 10.3390/ph15111385

Recommended Reading

Migraine in children and teens: managing the pain
Migraine ICYMI
Commentary: Risk factors and treatment for pediatric migraine, December 2022
Migraine ICYMI
High drug costs exclude most neurology patients from cutting-edge treatment
Migraine ICYMI
Evidence supporting atogepant as a promising treatment for migraine prevention
Migraine ICYMI
Alcohol as a trigger for migraine: What is the link?
Migraine ICYMI